Ral signaling pathway in health and cancer. (18th October 2017)

• Record Type: Journal Article
• Authors: Moghadam, Adel Rezaei; Patrad, Elham; Tafsiri, Elham; Peng, Warner; Fangman, Benjamin; Pluard, Timothy J; Accurso, Anthony; Salacz, Michael; Shah, Kushal; Ricke, Brandon; Bi, Danse; Kimura, Kyle; Graves, Leland; Najad, Marzieh Khajoie; Dolatkhah, Roya; Sanaat, Zohreh; Yazdi, Mina; Tavakolinia, Naeimeh; Mazani, Mohammad; Amani, Mojtaba; Ghavami, Saeid; Gartell, Robyn; Reilly, Colleen; Naima, Zaid; Esfandyari, Tuba; Farassati, Faris
• Is Part Of: Cancer medicine. Volume 6:Number 12(2018:Dec.)
• Page Start: 2998
• Page End: 3013
• Publication Date: 2017-10-18
• Subjects: Aurora Kinase -- biology -- cancer -- cancer stem cells -- Ral -- therapy; 616.994005
• DOI: 10.1002/cam4.1105
• Languages: English
• ISSNs: 2045-7634

Abstract

Abstract: The Ral (Ras‐Like) signaling pathway plays an important role in the biology of cells. A plethora of effects is regulated by this signaling pathway and its prooncogenic effectors. Our team has demonstrated the overactivation of the RalA signaling pathway in a number of human malignancies including cancers of the liver, ovary, lung, brain, and malignant peripheral nerve sheath tumors. Additionally, we have shown that the activation of RalA in cancer stem cells is higher in comparison with differentiated cancer cells. In this article, we review the role of Ral signaling in health and disease with a focus on the role of this multifunctional protein in the generation of therapies for cancer. An improved understanding of this pathway can lead to development of a novel class of anticancer therapies that functions on the basis of intervention with RalA or its downstream effectors. Abstract : Ral signaling pathway as an important effector pathway downstream of Ras plays an important role in health and diseases.